Clinical trials: Refractory Shock
Shock Hypovolemic, Shock, Septic
Management of Shock in Children With SAM or Severe Underweight and Diarrhea
Diarrhea is one of the leading causes of under-five childhood mortality and accounts for 8% of 5.4 million global under-5 deaths.
- Conditions
- Shock Hypovolemic, Shock, Septic, Blood Transfusion, Adrenaline
- Trial name
- NCT04750070
- Testing
- Blood and Dopamine, Blood and adrenaline
- Where
- Bangladesh
- Volunteers
- 135 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Relapsed or Refractory Neuroblastoma
A Phase I Trial of Anti-GD2 T-cells (1RG-CART)
The purpose of this first in human study is to determine the safety and feasibility of 1RG-CART therapy in patients with relapsed or refractory neuroblastoma.
- Trial name
- NCT02761915
- Testing
- Leukapheresis, Cyclophosphamide, Fludarabine
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Cancer Research UK
Septic Shock
Stress Hydrocortisone In Pediatric Septic Shock
SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and…
- Trial name
- SHIPSS (NCT03401398)
- Testing
- Hydrocortisone, sodium succinate, Normal saline
- Where
- 44 sites in United States, Brazil and 8 more
- Volunteers
- 500 people
- Sponsor
- Jerry Zimmerman
Neonatal Sepsis, Shock, Septic
Intravenous Methylene Blue for Treating Refractory Neonatal Septic Shock
Preterm infants (born at less than 37 weeks of pregnancy) sometimes develop a serious blood infection leading to low blood pressure, which does not respond to saline or to the standard medicines for increasing blood pressure…
- Trial name
- NCT06306001
- Testing
- Methylene Blue
- Where
- India
- Volunteers
- 130 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Septic Shock, Extracorporeal Membrane Oxygenation Complication
Study on the Efficacy and Timing of ECMO Therapy in Children With Refractory Septic Shock
Severe sepsis and septic shock remain the leading causes of child mortality worldwide. Sepsis is a complex process that ultimately leads to circulation disorders, organ perfusion abnormalities, capillary leakage, tissue hypoxia…
- Trial name
- NCT03948048
- Testing
- ECMO
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Children's Hospital of Fudan University
Malignant Peripheral Nerve Sheath Tumors (MPNST), Sarcoma
SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
Phase 1: To assess the safety, tolerability, and maximum tolerated dose (MTD)/ recommended dose of ganetespib when administered in combination with sirolimus in patients with refractory or relapsed sarcomas including unresectable…
- Trial name
- NCT02008877
- Testing
- ganetespib, Sirolimus
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Neonatal Sepsis, Refractory Shock
Methylene Blue Versus Vasopressin Analogue for Treatment of Septic Shock in Preterm Neonate
A randomized, prospective study comparing methylene blue versus terlipressin in treatment of catecholamines resistant shock in preterm neonate
- Trial name
- NCT04110418
- Testing
- Methylene Blue
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Ain Shams University
Septic Shock
Dopamine Versus Epinephrine for Pediatric Fluid-Refractory Hypotensive Septic Shock
This randomized clinical trial was conducted to compare dopamine with epinephrine as the first vasoactive treatment in children aged 2 to 12 years with fluid-refractory hypotensive septic shock.
- Trial name
- NCT07775001
- Testing
- Epinephrine, dopamine
- Where
- Pakistan
- Volunteers
- 66 people
- Sponsor
- Nishtar Medical University
Vasodilatory Shock
Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension
The goal of this clinical trial is to determine the safety and efficacy of Angiotensin-II in the treatment of pediatric patients in fluid refractory vasodilatory shock.
- Trial name
- NCT07212686
- Testing
- Angiotensin-II
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwell Health
Fluid Refractory Septic Shock, Septic Shock
Adrenaline V/s Dopamine in Fuid Refractory Septic Shock
This study compares the efficacy of two drugs i.e Adrenaline and dopamine in fluid refractory type of septic shock which is a dreadful medical condition especially in children.
- Trial name
- NCT07273526
- Testing
- Adrenaline, Dopamine
- Where
- Pakistan
- Volunteers
- 90 people
- Sponsor
- Laiba Qamar
Septic Shock, Refractory Shock
What Should be the Next Vasopressor for Severe Septic Shock? Methylene Blue or Terlipressin
The ICU mortality rate of patients with septic shock was still high upto 54.1%.In first 6 hours of resuscitation, the goals of resuscitation in sepsis shock after adequate fluid resuscitation is MAP ≥65 mmHg.
- Trial name
- NCT03038503
- Testing
- Methylene Blue, Terlipressin
- Where
- Thailand
- Volunteers
- 60 people
- Sponsor
- Ramathibodi Hospital
Acute Lymphoblastic Leukemia, Immune System Diseases
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
The body has different ways of fighting infection and disease. No single way is effective at fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells.
- Conditions
- Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders
- Trial name
- NCT03016377
- Testing
- iC9-CAR19 cells, Rimiducid, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
COVID, SARS-CoV-2
European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO
In the last 10 years, severe acute respiratory infection (SARI) was responsible of multiple outbreaks putting a strain on the public health worldwide.
- Conditions
- COVID, SARS-CoV-2, ARDS, Human, Refractory Hypoxemia
- Trial name
- EuroECMO-COVID (NCT04366921)
- Where
- 97 sites in Austria, Belgium and 17 more
- Volunteers
- 150 people
- Sponsor
- Maastricht University Medical Center